Intraperitoneal injections of EGFR-targeted sgPLK1-cLNPs caused their selective uptake into disseminated ovarian tumors, enabled up to approximately 80% gene editing in vivo, inhibited tumor growth and increased survival by 80% [74]. Here, EGFR is linked to neoplasm.